🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise worldwide, with estimates suggesting in excess of 82 million instances each year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Results and Global Access

Based on findings detailed in a prominent scientific publication, the new drug successfully treated more than 90% of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which combines two antibiotics. The trial enrolled hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have shared positive views. The availability of a one-pill regimen like this is described as a "critical tool" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.